Peijia Medical Limited (HKG: 9996)

Market Cap	2.62B
Revenue (ttm)	556.01M
Net Income (ttm)	-270.49M
Shares Out	654.14M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,000
Open	3.860
Previous Close	3.850
Day's Range	3.860 - 4.060
52-Week Range	2.160 - 8.340
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Peijia Medical

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusMax, an iteration steerable TAVR system; TaurusTrio, a TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymeric leaflet TAVR system; Tri...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 973
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9996

Financial Performance

In 2023, Peijia Medical's revenue was 441.13 million, an increase of 75.86% compared to the previous year's 250.83 million. Losses were -392.53 million, -3.75% less than in 2022.

Financial numbers in CNY